EMA Guidance on Trial Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
The impact of COVID-19 on ongoing trials, on opening a new trial site in an existing trial, ongoing recruitment and continued involvement of participants in the trial, or on starting of new trials needs to be considered. Read this EMA Guidance to learn more about managing your clinical trials during this pandemic.
Related Education Resources.
All ResourcesEAP 104: EAP Communication and Stakeholder Management
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
The Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
Industry Evolution – A Vision of the Clinical Supply Chain in the Next Decade
Topic: Supply Chain
White Paper
Free
